QUEBEC CITY, April 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Prof. Frans M.J. Debruyne, M.D., Ph.D., Chairman and CEO of Andros Men's Health Institutes in The Netherlands, won the award for Best Poster Presentation in a Poster Session at the 23rd Annual European Association of Urology Meeting, which was held March 26-28, 2008 in Milan, Italy. Titled "LHRH antagonist cetrorelix for symptomatic BPH: Prolonged improvement beyond end of treatment in placebo-controlled trials." FMJ Debruyne, A.A. Gres, A. Bantschev, M. Tzvetkov, K. Grdovic, the poster referred to previously disclosed results from two Phase 2 trials with cetrorelix in benign prostatic hyperplasia (BPH), which showed a prolonged duration of effect extending far beyond the end of the short-term treatment course.
Prof. Jurgen Engel, Ph. D., Executive Vice President, Scientific
Affairs at AEterna Zentaris commented, "We would like to congratulate
Professor Debruyne for this prestigious award which acknowledges his
significant contribution to the quality and achievements of our drug
development program with cetrorelix in BPH. The data observed in these
Phase 2 trials warranted our current extensive Phase 3 program with
cetrorelix in this same indication and we look forward to presenting the
results in Q3 2009, as stated previously. We believe cetrorelix could
provide a novel, efficient, convenient and safe treatment for the millions
of men with BPH."
Introduction and Objectives
Preliminary studies indicated prolonged, unmaintained improvement in
signs and symptoms of BPH after short courses of cetrorelix. Tw
|SOURCE AETERNA ZENTARIS INC.|
Copyright©2008 PR Newswire.
All rights reserved